My guess is the next major event that the market will be forced to take notice will be if and when FDA blesses with one of those designations for the trials (AA, BTD, etc.).
Depending on the type of feedback it provides FDA can move the pps (either way). Do not know how often the market has ignored the FDA's input, especially concerning small biotechs(we know how stocks tank when the FDA disapproves; in case of AVXL we are talking of CNS diseases with favorable trial results).